AstraGin® receives positive clinical study results on its 90-day toxicity study
Nuliv Science, a nutraceutical ingredient developer & research institute, announced today that it received clinical study results for its 90-Day Toxicity Study on its flagship ingredient, AstraGin®, a wellness & absorption enhancing ingredient.
The study sponsored by NuLiv Science was carried out to evaluate the toxicity of AstraGin®, after 90 days repeated administration by oral route in Wistar rats, to evaluate the characterization of the test item toxicity, for an indication of the dose-response relationship and the determination of the No-Observed Adverse Effect Level (NOAEL).
In keeping with best practices, the study was framed within the OECD Guideline for the Testing of Chemicals No. 408 “Repeated Dose 90-Day Oral Toxicity Study in Rodents”; adopted September 21, 1998.
“We completed a 28-day sub-acute toxicity study but wanted to evaluate a longer time span. A 90-day study evaluating same dosage ranges confirmed that AstraGin® is safe for consumption”, said Richard Wang, General Manager of NuLiv Science.
Based on observations and analysis in the study, it was concluded that Astragin® did not produce any significant changes in physical, physiological, neurobehavioral, biochemical, hematological and histopathological parameters in any of the doses used in the current study.
Furthermore, there were no treatment-related changes that were considered to be of toxicological significance. Results of the current study support the safety of AstraGin® in Wistar rats.
Wang commented, “We hope that additional safety studies will provide reassurance to end users, industry and government alike.”